Views:0 Author:Site Editor Publish Time: 2021-10-25 Origin:Site
As methyl cinnamate supplier, the company specializes in cinnamon series, including cinnamic acid, cinnamaldehyde, cinnamic alcohol, methyl cinnamate, ethyl cinnamate and so on. The company can also accept the customization of other cinnamon derivatives.
As methyl cinnamate supplier, Wuhan LANDMARK Industrial Co., Ltd. was established in 2012 and is located in Wuhan City, Hubei Province.
The company is a comprehensive high-tech enterprise integrating research, production and sales.
As methyl cinnamate supplier, the LANDMARK headquarters is located in Dongxihu District, As aromatic chemical supplier, Wuhan City, which is the sub-provincial-level central city of six provinces in central China, with convenient land and water transportation radiating nationwide.
We are a growing company committed to continually enhancing the employee experience and remaining a clean, efficient and safe work environment.
As methyl cinnamate supplier, the company has the advanced production equipment, modern facilities, domestic advanced production technology and mature quality management system.
As methyl cinnamate supplier, the company has years of experience in the production and development of benzaldehyde downstream products, with 5 master degree engineers, 25 undergraduate technicians, and 3000MT annual output of cinnamaldehyde, 1000MT of cinnamic acid, 600MT of cinnamyl alcohol and 600MT of methyl cinnamate.
As methyl cinnamate supplier, the company has passed ISO9001 International Quality Management System certification, and relying on the concept of independent development and joint development of universities, it has in-depth cooperation with major universities and scientific research institutions in Wuhan.
As a result of our quality control measures, our company has also got FDA certificate. In the meantime, it has successively awarded “The Excellent Companie of Integrity Standards”, “Top Ten Outstanding Private Enterprises”, and “The AAA-level Credit Enterprises”, etc.
As methyl cinnamate supplier, Ed biological company focuses on the field of molecular diagnosis of tumor precision medicine, focuses on the technological innovation of benefiting the people with science and technology, and is committed to providing patients with compliant and high-quality diagnostic products and services, so that patients can truly benefit from precision medicine.
As methyl cinnamate supplier, the company has the qualifications of national enterprise technology center, postdoctoral scientific research workstation, gene detection technology application demonstration center of national development and Reform Commission, national high-tech enterprise and Fujian cancer high throughput sequencing Engineering Research Center.
The GMP standard plant has obtained the qualification certification of National Drug Administration (nmpa) and European Union ISO13485
As methyl cinnamate supplier, the company's products cover all major cancer types with accurate medical conditions, and many products have no competitive products so far.
In addition to large-scale application in domestic top three hospitals, some products have been approved to be listed in Japan and South Korea and entered local medical insurance, creating a precedent for overseas approval of tumor concomitant diagnosis in China.
As methyl cinnamate supplier, the company has a medical institution practice license and has passed the certification of the American Society of Pathology (CAP), specializing in third-party clinical examination services.
At present, customers in dozens of countries and regions all over the world choose ade products and services, which benefits hundreds of thousands of tumor patients every year, effectively avoiding the misuse and abuse of tumor drugs.
As methyl cinnamate supplier, Junshi biological company is committed to the discovery and development of innovative drugs, as well as clinical R & D and commercialization all over the world.
As methyl cinnamate supplier, the purpose of the company is to provide patients with better and lower cost treatment options. Using the core platform technology of protein engineering, we are at the forefront of macromolecular drug research and development.
In China, we are in a leading position in the treatment of tumor immunotherapy, autoimmune diseases and metabolic diseases with excellent innovative drug discovery ability, advanced biotechnology R & D, large-scale production technology of the whole industry chain and rapid expansion of the combination of drugs under research with great market potential.
We aim to develop first in class or best in class drugs through source innovation and become a pioneer in the field of translational medicine.
With the enrichment of product pipelines and the exploration of drug combination therapy, it is expected that our innovation field will expand to more types of drug research and development, including small molecule drugs and antibody drug conjugates (or ADCs), as well as the exploration of the next generation of innovative therapies for cancer and autoimmune diseases.